Osteoporosis-pseudoglioma syndrome: Description of 9 new cases and beneficial response to bisphosphonates
详细信息 查看全文
- 作者：Elizabeth A. Streeten ; Daniel McBride ; Eric Puffenberger ; Marc E. Hoffman ; Toni I. Pollin ; Patrick Donnelly ; Paul Sack ; Holmes Morton
- 关键词：Osteoporosis-pseudoglioma ; Compound heterozygote ; Juvenile osteoporosis ; Blindness ; LRP5
- 刊名：Bone
- 出版年：2008
- 出版时间：September 2008
- 年：2008
- 卷：43
- 期：3
- 页码：584-590
- 全文大小：450 K
文摘
Osteoporosis-pseudoglioma syndrome (OPPG) is a rare autosomal recessive disorder of severe juvenile osteoporosis and congenital blindness, due to mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene. Approximately fifty cases of OPPG have been reported. We report 9 new cases of OPPG, in three related nuclear families of Conservative Mennonites in Pennsylvania. All 9 children with OPPG were blind and had osteoporosis. Four of six parents had low bone mineral density (BMD) or osteoporosis; 2 were normal. Sequence analysis from genomic DNA revealed homozygosity for a nonsense mutation of exon 6 of LRP5 (W425X) in four OPPG cases tested in families A and C. In family B, OPPG cases were compound heterozygotes for the exon 6 W425X LRP5 mutation and a second exon 6 mutation (T409A); bone phenotype was milder than in family A. Neither of these mutations was present in an unrelated normal. The four treated OPPG patients all responded to bisphosphonates (duration 1.5–6.5 years) with improvement in Z-scores. One patient had a negligible response to teriparatide. In summary, we report 9 new cases of OPPG due to two novel LRP5 mutations, note a milder bone phenotype but similar ocular phenotype in LRP5 W425X/T409A compound heterozygotes than in W425X homozygotes and describe positive response to bisphosphonate treatment in four cases.